Journal of Virus Eradication

Article	Citations
Hepatitis B prevalence and associated factors in adults presenting for infection screening in northern Thailand	61
A viewpoint: The 2022 monkeypox outbreak	14
CHIME - A tailored HCV microelimination project in Viennese people who inject drugs at drug centralized substitution centers	11
Combination of dasabuvir and PSI-6206 for the treatment of coxsackievirus B3 infection	11
Editorial	11
OP 8.5 – 00104 TGF-beta Blockade to Stop HIV White Noise: a New “Release and Kill” HIV Strategy	9
Comparative sensitivity of automated (Abbott M2000) and manual plasma HIV-1 RNA PCR assays for the detection of persistent viremia after long-term antiretroviral therapy	9
PP 8.7 – 00098 The sequestration and expansion of effector lymphocytes in lymphoid tissue using combination FTY720 and N-803 immunotherapy at ART initiation fails to limit SIV persistence	8
Table of Contents	8
PP 3.8 – 00137 Characterization of the HIV-1 subtype C reservoir during ART in South-African men and women	7
PP 3.3 – 00071 Longitudinal proviral landscape and reservoir dynamics in a unique case of HIV superinfection	7
PP 3.16 – 00209 Prolonged persistence of HIV-infected cells in tissues after allogeneic hematopoietic transplant	7
PP 3.10 – 00168 Vpr synergizes with vorinostat to prevent HIV-1 latency establishment	7
OP 6.1 It's a mountain not a hill: Progress made in realizing AAV-delivered inhibitors for an HIV cure	6
OP 4.4 – 00018 HIV reservoir burden associates with numbers of HIV-specific CD8+ T cells under long-term antiretroviral therapy and prevents them from differentiating into functional memory cells	6
PP 4.25 – 00196 The Role of Epigenetics in Mediating Neuronal Circuitry and Maladaptive Neuronal Changes in HIV and Opioid Drug Addiction	6
OP 6.7 – 00044 Long-term ART-free SIV Remission Following Allogeneic Hematopoietic Cell Transplantation in Mauritian Cynomolgus Macaques	6
PP 4.9 – 00113 Transcription of Defective HIV Proviruses Trigger Innate Immune Responses	6
OP 5.2 – 00070 Characterization of a dual PTPN1/PTPN2 inhibitor to target latent HIV reservoirs	5
OP 1.10 – 00210 Clonal Dynamics within HIV-Infected CD4 T Cell Reservoirs after PD-1 Blockade under ART	5
OP 4.6 – 00185 No associations between magnitudes of HIV-specific CTL responses on stable art and subsequent decay of intact proviruses or cell-associated HIV mRNA	5
PP 3.1 – 00058 Development of a digital PCR assay to profile HIV expression at single-infected-cell resolution	5
PP 5.5 – 00026 Targeting Tat/TAR interactions with the superelongation complex for the development of novel treatments for HIV/AIDS	5
PP 4.18 – 00213 Dynamics and antiviral role of TOX+ TCF1+ CD39+ CD8 T cells in lymphoid tissue of SIV-infected rhesus macaques	5
OP 6.5 – 00164 Nanobody-engineered AAV vectors for CD4-targeted gene therapy	5

PP 3.9 – 00146 Impact of time on antiretroviral therapy on the proviral reservoir in people living with HIV	5
PP 1.28 – 00156 The HIV-1 antisense RNA Ast promotes viral latency via epigenetic silencing of the proviral 5′LTR and is expressed in latently infected cells from ART-suppressed donors	4
PP 1.14 – 00094 Development of an immunocytochemistry assay to quantify the translationally active HIV reservoir	4
OP 2.4 – 00145 No Evidence of Ongoing Viral Replication in SIV-Infected Macaques on Combination Antiretroviral Therapy Initiated in the Chronic Phase of Infection Despite Elevated Residual Plasma Vira	4
PP 1.10 – 00069 Isotretinoin enhances IL-15 mediated HIV latency reversal and reduces the inducible latent reservoir	4
PP 2.11 – 00144 Transcriptional and translational SIV profiles of peripheral and lymphoid CD4+ T cells of viremic and ART-suppressed Rhesus macaques	4
PP 1.33 – 00167 Integrated single-cell multi-omic profiling of HIV latency reversal	4
PP 2.12 – 00153 eCD4-Ig-DNA Decreased HIV Reservoir and Delayed Viral Rebound Through Fc Mediated Functions in BLT Humanized Mice	3
OP 1.6 – 00138 Role of UHRF1 in HIV-1 transcriptional repression through epigenetic and non-epigenetic mechanisms	3
Motivations, barriers and experiences of participants in an HIV reservoir trial	3
Factors associated with unquantifiable total HIV-1 DNA in peripheral blood in persons living with HIV: An observational study	3
PP 2.13 – 00160 Enhancing Tolerability and Efficacy of Latency Reversing Agents in “Kick and Kill” HIV Cure Approaches	3
The evidence for using tenofovir disoproxil fumarate plus lamivudine as a nucleoside analogue backbone for the treatment of HIV	3
Barriers that prevent adults living with HBV infection from participating in clinical research: experience from South Africa	3
Editorial JVE 8.3	3
PP 2.8 – 00124 Spironolactone Represses HIV-1 Driven Transcription in Human Microglia and T cell Models of Latency and Alters DNA Methylation of Metabolic Genes	3
PP 2.15 – 00169 Macrophages are the primary source of virus in semen and male genital tract organs in acutely and chronically infected rhesus macaques	3
Existing knowledge, myths, and perceptions about hepatitis B and liver cancer within highly impacted immigrant communities	3
Efficacy of the hepatitis B vaccine alone in the prevention of hepatitis B perinatal transmission in infants born to hepatitis B e antigen-negative carrier mothers	3
PP2.4 – 00157 Development of a Virology Quality Assurance Program to Assess Inter-lab Reproducibility of HIV-1 Reservoir Assays	2
PP2.6 – 00048 The HIV reservoir can be established in either quiescent or senescent CD4 T cells	2
6.4 – 00112 Overcoming immune responses directed toward AAV-delivered bNAbs	2
8.5 – 00015 Changes in the composition of HIV-1 reservoir of PWH on ART and dasatinib	2
Achievements and gaps to provide pre-exposure prophylaxis (PrEP) for women across the European Region – Results from a European survey study	2
1.1 – 00003 Longitudinal analysis in early treated individuals reveals alteration in the HIV-1 integration site landscape and composition of the inducible reservoir	2
7.5 – 00009 Postmortem analyses of the central nervous system in individuals with HIV demonstrate that infection of microglia contributes to inflammatory pathways despite viral suppression	2
3.5 – 00053 Monovalent SMAC mimetics enhance proliferation of HIV-specific CD8 T cells	2
7.2 – 00123 Peptide-induced apoptosis of latently infected cells and reduction of the HIV reservoir in people living with HIV: preliminary results of a clinical trial	2
PP3.6 – 00064 Novel synthesized protein kinase C modulators show enhanced HIV latency reversal properties and synergize with a BET bromodomain inhibitor	2
PP3.7 – 00002 Towards a functional cure for HIV-1 infection: BRD4 modulator ZL0580 and LEDGINs additively block and lock HIV-1 transcription	2
PP8.7 – 00066 Characterization and Optimization of AAV Transgene Cassettes Expressing HIV-1 Broadly Neutralizing Antibody 10-1074	1
Editorial 10.3	1
Launching a multidisciplinary European collaboration towards a cure for HIV: The EU2Cure Consortium	1
Where do those data go? Reuse of screening results from clinical trials to estimate population prevalence of HBV infection in adults in Kilifi, Kenya	1
A systematic review of limiting antigen avidity enzyme immunoassay for detection of recent HIV-1 infection to expand supported applications	1
OP 6.6 – 00134 Viral Suppression in SHIV-infected Rhesus Macaques following AAVmediated Delivery of Closer-to-germline Monoclonal Antibodies	1
Interrupting antiretroviral therapy in HIV cure trials during COVID-19: Adaptation to low transmission settings	1
PP 3.12 – 00180 Distinct HIV-1 resistance profiles against bNAb in intact vs defective viral genomes	1
HIV remission trial investigators’ attitudes towards risk and risk mitigation in trials that include treatment interruption	1
PP1.19 – 00036 Unexpected Redundancy of the TNF/NF-kB Axis in HIV-1 Restriction and Latency Reversal in Primary Human MDM Polarized to M1 Cells	1
PP 8.11 – 00174 Distinct HIV reservoir characteristics among individuals treated during primary versus chronic HIV infection	1
PP1.5 – 00132 Tunneling Nanotubes are essential for the propagation of HIV infection at early stages of infection and reactivation	1
PP 7.11 – 00091 In vivo and in vitro imaging of viral reservoirs to understand bystander damage during chronic HIV infection	1
PP 7.8 – 00060 Slowing or Reversal of Decay of Intact Proviruses Over Two Decades of Suppressive ART	1
Editorial Board	1
Understanding participant perspectives around HIV-1 cure-related studies involving antiretroviral analytical treatment interruptions in the United Kingdom	1
Editorial Board	1
PP6.5 – 00086 Regulation of AAV transgene expression using nanoparticledelivered Cre-recombinase	1
PP4.4 – 00151 Trained immunity as an exacerbating factor in Chronic HIV and HIVAssociated Neurocognitive Disorders	1
Cascade of care among hepatitis B patients in Maastricht, the Netherlands, 1996 to 2018	1

PP 4.7 – 00097 Signatures of HIV-Infected CD4+ T Cell Resistance to NK Cell-Mediated Cytotoxicity	1
Development of a latency model for HIV-1 subtype C and the impact of long terminal repeat element genetic variation on latency reversal	1
PP 5.4 – 00184 Optimization of Smac Mimetics as HIV-1 Latency Reversing Agents	1
Virological and serological outcomes in people with HIV-HBV coinfection who had discontinued tenofovir-containing antiretroviral therapy: Results from a prospective cohort study	1
Editorial Board	1
PP 3.6 – 00122 Heterogeneous associations between HIV genomic integrity and proviral longevity during long-term ART	1
4.2 – 00027 Secondary cytotoxicity of memory CD8+ T cells targeting autologous HIV during treated chronic infection is associated with suppression of provirus and of recrudescent viremia	1
OP 8.3 – 00028 HIV-vaccine induced, broad and polyfunctional CD4 and CD8 T cell responses are associated with prolonged time off ART and lower pVL at the end of ATI in the AELIX-002 therapeutic vaccin	1
PP 7.4 – 00016 Acquisition of SARS-CoV-2 infection during an HIV cure study with an ATI period	1
PP 8.13 – 00191 Investigating the Impact of CD4 mimetic BNM-III-170 on SHIV-infected Rhesus Macaques	1
Evaluation of HIV-1 DNA levels among adolescents living with perinatally acquired HIV-1 in Yaounde, Cameroon: A contribution to paediatric HIV cure research in Sub-Saharan Africa	1
Highlights of HIV Cure in IAS, Montréal	1
ST1.3 – 00171 Venetoclax decreases intact proviral DNA frequency in SIV-infected, ART-suppressed Rhesus Macaques	1
Key highlights from the international AIDS society (IAS) conference 2021	1
Table of content	1
Unwillingness of patients in Ghana to interrupt antiretroviral therapy for HIV cure research	1
8.2 – 00072 Early intervention with an indoline CD4-mimetic compound that sensitizes HIV-1-infected cells to ADCC favors post-treatment HIV control in humanized mice	1
The central nervous system is a potential reservoir and possible origin of drug resistance in hepatitis B infection	1
The perceived impact of an HIV cure by people living with HIV and key populations vulnerable to HIV in the Netherlands: A qualitative study	1
Hepatitis B prevalence in an endemic area of hepatitis C virus: A population-based study implicated in hepatitis elimination in Thailand	1
Editorial JVE 10.2	1
Highlights from the Tenth International Workshop on HIV Persistence during Therapy, December 13-16, 2022, Miami, Florida-USA	1
PP6.6 – 00076 Target cell-specific nanobody-engineered AAV vectors for in vivo gene therapy approaches for HIV cure	1
PP 3.5 – 00110 The proviral quasispecies of HIV-1	1
PP5.10 – 00033 Ex vivo HIV DNA integration in STAT3 drives T cell persistence—A model of HIV-associated T cell lymphoma	1
OP 8.2 – 00033 Interleukin-2 administration is a potent latency reversal agent in people with treated HIV infection	1
PP 4.17 – 00198 Peripheral Blood Biomarkers of Occult Infection in ART-Suppressed, SIV-Infected Rhesus Macaques	1
Persistent HIV-1 transcription in CD4+ T cells from ART-suppressed individuals can originate from biologically competent proviruses	1
Highlights from the virtual conference on retroviruses and opportunistic infections (CROI) 2021: SARS-CoV-2 pathogenesis, new data about antiretroviral treatments, HIV-associated comorbidities, pediat	1
Highlights of the Conference on Retroviruses and Opportunistic Infections, 12–16 February 2022, virtual	1
6.6 – 00176 CAR/CCR9 T cell immunotherapy shows promise in localization of SIV-specific CAR T cells to the gastrointestinal tract of rhesus macaques	0
PP 1.43 – 00206 Evaluating integrated HIV-1 quasispecies using Near Full Length sequencing in ART-suppressed individuals in the Drexel CARES Cohort	0
PP3.3 – 00121 Exploring the Effects of Benzodiazepines on a Novel Mechanism of Control in HIV-1 Infected Human Monocyte Derived Macrophages	0
OP 3.4 – 00197 Infected naïve CD4+ T cells in children with HIV can proliferate and persist on ART	0
PP 3.19 – 00062 The Role of Pannexin-1 channels in HIV infection and persistence	0
PP 1.40 – 00074 Blood Brain Barrier Pericytes and the Molecular Impact of Active and Latent HIV Infection	0
4.4 – 00091 Molecular Drivers of HIV-Induced Immune Modulation and CD8+ T Cell Dysfunction in Lymph Node Follicles during ART-Suppressed Subtype C Infection	0
OP 2.5 – 00048 Targeting the SIV reservoir with Alemtuzumab	0
PP 4.10 – 00119 Multiomic dynamics of the cellular HIV reservoir after rebound during ATI	0
PP6.3 – 00073 Blocking HIV-1 replication by disrupting TAR-Tat-Cyclin T1 interactions using double-strand break- (DSB-) free CRISPR editing	0
Adaptation of the intact proviral DNA assay to a nanowell-based digital PCR platform	0
PP8.2 – 00162 Protective MHC-1 alleles extend time to SIV rebound following neutralizing antibody treatment at time of ART release	0
PP 8.2 – 00015 Retargeting cytomegalovirus-specific CD8+ cytotoxic T lymphocytes to kill HIV/SIV-infected cells via peptide-MHC Iantibody fusion proteins	0
OP 1.5 – 00046 P400/Tip60 chromatin remodeling complex in HIV transcription and latency establishment	0
1.3 – 00084 Persistence of HIV genomes in bacteria-specific CD4+ T cells during ART	0
3.1 – 00145 Exploring novel HIV Tat inhibitors	0
PP 2.6 – 00043 Probing cell death pathways in response to NNRTI treatment using a THP-1 infection model	0
PP 1.4 – 00037 Histone decrotonylation uniquely regulates HIV-1 transcription and can be modulated to control HIV-1 latency	0
2.5 – 00074 Propagation of HIV reservoir clones reveals functional heterogeneity, suggesting diverse mechanisms of persistence	0
PP 7.6 – 00036 Single cell transcriptomics identifies PTMA as a host gene that inhibits HIV during acute infection in vivo	0
Sulforaphane prevents the reactivation of HIV-1 by suppressing NFκB signaling	0
Rate of occult hepatitis B virus infection among individuals with tuberculosis in northeastern Iran: A molecular epidemiological study	0
PP 1.17 – 00103 The Ubiquitin Ligase ITCH and CPSF6 Control HIV Transcription	0
PP8.4 – 00154 Using Immunomodulatory Drug Pretreatment to Enhance AAV Delivery of Anti-HIV Broadly Neutralizing Monoclonal Antibodies	0
Highlights of the first edition of the European Conference on Microbiota & Virology: A hybrid event, Paris, 23 March 2023	0
Bringing social context into global biomedical HIV cure-related research: An urgent call to action	0
Highlights of the HIV cure session, 19th European AIDS Clinical Society (EACS) Conference, 18-21 October 2023, Warsaw, Poland	0
Relatively high interest but limited active engagement in HIV cure research: Awareness, interest, and information-seeking among affected communities in the Netherlands	0
Hepatitis B birth dose vaccination for newborns in Uganda: A qualitative inquiry on pregnant women's perceptions, barriers and preferences	0
PP 3.13 – 00189 HIV-1-infected individuals with extremely low reservoir under ART are characterized by reduced viral diversity and higher levels of hypermutations in their viral reservoirs	0
PP 1.16 – 00100 Single-cell multiomics analysis reveals distinct mechanisms of HIV persistence in memory CD4+ T cell subsets from tissues	0
From awareness to action: Unveiling knowledge, attitudes and testing strategies to enhance human papillomavirus vaccination uptake in Jordan	0
PP1.1 – 00164 Nuclear retention of unspliced HIV-1 RNA as a novel reversible posttranscriptional block in latency	0
PP 4.19 – 00021 Impact of SARS-COV-2-Mediated CD4 T Cell Activation HIV DNA Persistence In Vivo	0
Staging of immuno-virological dynamics during acute HIV infection in a Belgian prospective cohort study	0
A comparison of sofosbuvir/velpatasvir and glecaprevir/pibrentasvir for the treatment of hepatitis C infection among people who inject drugs	0
Intact provirus and integration sites analysis in acute HIV-1 infection and changes after one year of early antiviral therapy	0
OP 4.7 – 00121 Circulating immune predictors of intact HIV reservoir decay during long-term ART	0
PP7.2 – 00169 Longitudinal Persistence of HIV DNA in CSF Over 4 Years Despite Up to 20 Years of ART	0
Evolution of anti-SARS-CoV-2 spike protein titers after two-dose of COVID-19 vaccination among people living with HIV	0
PP3.4 – 00100 Retinoids enhance NK effector functions against HIV infected CD4 T cells	0
PP 8.4 – 00061 Bispecific antibodies promote natural killer cell-mediated elimination of the HIV reservoir	0
5.6 – 00133 Suppression of viral rebound by a Rev-dependent lentiviral particle in SIV-infected rhesus macaques	0
Editorial Board	0
PP 4.3 – 00052 Intra- and extracellular levels of acyl-coA-binding protein and anti-HIV T-cell function in people living with HIV	0
7.6 – 00052 The Tuberculosis Associated Microenvironment Reduces CD8+ TCell Control of HIV at the Site of the Coinfection	0
PP 1.35 – 00172 A histone deacetylase network regulates epigenetic reprogramming and viral silencing in HIV infected cells	0
OP 1.3 – 00017 The fraction of cells with unspliced HIV RNA is not associated with plasma viremia	0
Hepatitis C in Uganda: Identification of infected blood donors for micro-elimination	0
PP 4.26 – 00201 Study of reservoir size and telomere length in children with perinatal HIV-1 infection who achieved late viral suppression	0

PP1.12 – 00061 Nanopore sequencing enables capturing of long HIV-1 reads for multi-omic analysis of HIV-1-infected cells	0
PP 1.24 – 00132 BET PROTACS Reveal BRD4 Disruption of the 7SK/P-TEFb Equilibrium is Critical for Effective Reactivation of Latent HIV in CD4+ T-cells	0
4.6 – 00114 Transcriptomic profile of gut T follicular helper cells during persistent HIV infection	0
PP 1.34 – 00170 Intestinal endothelial cells substantially increase HIV infection and latency in resting and activated CD4+ T cells, particularly affecting CCR6+ Th17 subpopulation	0
OP 7.2 – 00035 Impact of 10-1074LS and 3BNC117-LS on viral rebound dynamics following treatment interruption six months after dosing: four cases from the open label arm of the RIO trial	0
PP 4.6 – 00065 Retinoic Acid Transcriptionally Reprograms Macrophages for Increased Permissiveness to HIV-1 Replication	0
Editorial Board	0
4.3 – 00124 HIV infection induces T cell quiescence, leading to proviral latency	0
OP 2.7 – 00057 The latency reversing agent HODHBt synergizes with IL-15 to enhance cytotoxic function of HIV-specific CD8+ T-cells	0
PP 4.27 – 00202 Single-cell RNA sequencing reveals CBD genetic signature in monocyte gene expression	0
PP1.13 – 00083 The lysine methyltransferase SMYD5 methylates HIV-1 Tat K28/K29	0
ST2.3 – 00128 Targeting Myeloid Reservoirs Harboring Replication-Competent HIV	0
PP 8.6 – 00089 Ad26/MVA Mosaic vaccine induced antibody responses with limited cross-reactivity to CRF01_AE infections	0
OP 1.7 – 00194 Potent latency reversal enables in-depth transcriptomic analysis of the translation-competent HIV-1 reservoir	0
ST1.4 – 00008 Persistent HIV-1 unintegrated linear DNA can integrate and lead to viral replication after integrase inhibitor treatment removal	0
PP 1.11 – 00075 Selective nuclear retention of spliced and unspliced HIV-1 mRNAs following latency reversal	0
Host-directed therapy with 2-deoxy-D-glucose inhibits human rhinoviruses, endemic coronaviruses, and SARS-CoV-2	0
No evidence of neuronal damage as measured by neurofilament light chain in a HIV cure study utilising a kick-and-kill approach	0
PP 1.3 – 00022 Signaling pathways that activate P-TEFb to reverse HIV latency in CD4+ T cells	0
Disclaimer	0
PP 7.3 – 00010 Virion Immunocapture Reveals Low-level Myeloid-derived HIV Expression in Semen under INSTI-based Therapy is Disparate from Circulating Seminal and Blood Proviral Sequences	0
Editorial JVE 10.1	0
Community dialogue to enhance understanding of beliefs, behaviours and barriers to care for people living with liver disease and HBV infection in KwaZulu Natal, South Africa	0
PP 4.24 – 00176 Impact of cannabis use on immune cell populations and the viral reservoir in HIV-infected people on suppressive antiretroviral therapy	0
PP4.2 – 00163 Aging immune system alters HIV/SIV reservoirs	0
Menopause care in women living with HIV in the UK - A review	0
PP7.4 – 00075 Decoding HIV Suppression: Comprehensive Multi-Omics Analysis of Biomarkers and Gene Expression in Youth on Antiretroviral Therapy	0
PP5.1 – 00178 Impact of Methamphetamine use disorder on CNS reservoirs and beyond in SIV-infected rhesus macaques on antiretroviral therapy	0
Highlights from the 30th Conference on Retroviruses and Opportunist Infections (CROI)	0
Long-term outcome in people who use drugs successfully treated for hepatitis C infection with glecaprevir/pibrentasvir	0
PP 3.14 – 00190 Ex vivo response to latency reversal agents of CD4+ T cell subsets and monocyte derived HIV-1 subtype C LTR from individuals on suppressive cART	0
Prevention and control measures significantly curbed the SARS-CoV-2 and influenza epidemics in China	0
The poliovirus re-emergence: did concentrated efforts against COVID-19 open the door?	0
OP 2.8 – 00193 Enhancing PKC Modulator HIV Latency Reversing Agents	0
PP 6.4 – 00203 Construct a series of universal gRNAs targeting various regions within HIV	0
Polio eradication in Pakistan: Hope against hope or are we near eradication?	0
High prevalence of gastrointestinal manifestations among Cytomegalovirus end-organ disease in the combination antiretroviral era	0
Adeno-associated virus-vectored delivery of HIV biologics: the promise of a “single-shot” functional cure for HIV infection	0
PP 6.2 – 00106 CAR/CXCR5 T cells contact HIV vRNA+ cells in HIV-infected humanized DRAGA mice	0
PP4.7 – 00101 Immunotolerance during recent HIV infection and rapid disease progression	0
Combination strategies to durably suppress HIV-1: Soluble T cell receptors	0
PP1.18 – 00043 Blockade of mA machinery in HIV latently infected primary CD4+ T cells enhances HIV-1 transcription, RNA export and protein translation, and sensitizes cells for apoptosis	0
PP 1.8 – 00054 Integrative epigenomic and transcriptomic analysis reveals distinct regulations of mRNAs and lncRNAs in active versus latent HIV-1 infection of T cells	0
5.1 – 00136 Plasma SIVmacM clonotypes in rebound viremia correspond to those induced by AZD5582 during ART	0
Editorial 10.4	0
PP 4.8 – 00108 Presentation of cognate antigens by dendritic cells causes stochastic HIV expression	0
PP2.3 – 00168 Blocks to HIV transcriptional initiation, elongation, and splicing contribute differentially to inefficient virus reactivation across authentic reservoir-harboring CD4+ T-cell clones	0
PP 1.38 – 00212 Characterization of SIV infected mast cells in early foci of rebound after ATI and HIV infection of primary mast cells in tissue culture models reveals an important new player in viral	0
6.5 – 00173 A single-infusion of CCR5 modified stem-like CD4 T cells to limit HIV/SIV persistence during ART and promote control of viremia upon ATI	0
Phylogenetic signature and prevalence of natural resistance-associated substitutions for hepatitis C virus genotypes 3a and 3b in southwestern China	0
PP 6.3 – 00178 Targeting the human and macaque CCR5 genes using the CRISPR-SaCas9 gene-editing platform	0
PP 1.32 – 00163 cGAS/STING Signaling Drives HIV-1 Replication in Acutely Infected Macrophages	0
PP1.10 – 00098 Gene expression dynamics following dasatinib treatment and discontinuation in people with HIV-1: case report	0
PP 1.39 – 00086 The level of cell activation is associated with the pre-integrative latency of HIV linear DNA	0
OP 2.2 – 00200 Characterization of the SIV tissue reservoir transcriptional environment at the single focus level during ART and post ATI	0
PP8.1 – 00046 Safety, Viral Resuppression Dynamics, and Immunological Signatures of a PD-1 Inhibitor, Budigalimab, Among PWH During Analytical Treatment Interruption: Phase 1 Randomized Double- Blind	0
Population measles seroprevalence: Heterogeneity by birth-year cohort	0
PP4.13 – 00012 Distinct CD4 tissue-resident memory (TRM) depletion and CD8 TRM function between the small and large intestine indicate regionspecific mechanisms for gut pathology in people with HIV (P	0
PP 7.7 – 00055 Temporary increase in circulating replication-competent latent HIV-infected resting CD4+ T cells after switch to a Dolutegravir-based antiretroviral regiment	0
PP 7.2 – 00006 Acceptability of Home-Based Blood Collection Device for Viral Load Testing in HIV Cure Trials with Analytical Treatment Interruptions	0
PP 8.3 – 00049 Reduction in Markers of HIV Persistence with Gag/Pol/Il-12 DNA Therapeutic Vaccination	0
PP5.8 – 00137 HIV-infected macrophages display lysosomal release upon targeting by NK cells	0
PP 8.10 – 00155 Evaluation of HIV-specific T cell response in BEAT2 clinical trial	0
OP 1.9 – 00042 Measuring the impact of early 3BNC117 intervention at ART initiation on the productive reservoir in a cohort of diverse viral subtypes: results from the VIP-SPOT assay in the eCLEAR tri	0
PP4.6 – 00115 Disruption of intestinal germinal centers during HIV infection	0
The build-up of stock of stable integrated proviruses overtime explains the difficulty in reducing HIV-1 DNA levels when treatment is initiated at the chronic stage of the infection	0
7.4 – 00119 Anatomic distribution of HIV-infected clones in tissues after longterm antiretroviral therapy	0
Editorial Board	0
PP 1.15 – 00095 Proviruses persisting during the initial years of suppressive ART are relatively stable in terms of genetic diversity, clonal composition, and inferred integration date distribution	0
5.3 – 00106 Macrophage-tropic TF SHIV D infected NHP model of reservoir persistence, decay and pathogenesis on suppressive anti-retroviral therapy	0
OP 5.3 – 00082 1-year treatment with ponatinib provides protection of CD4+T cells against HIV that is maintained at least 1 year more after treatment interruption	0
A cohort analysis of sexually transmitted infections among different groups of men who have sex with men in the early era of HIV pre-exposure prophylaxis in France	0
2.3 – 00078 Detection of HIV-1 antisense transcripts in donor samples before and during ART	0
Assessing favipiravir impact on SARS-CoV-2 transmission within households: Insights from a multi-center study (FaviPrev)	0
Antiviral activity of silver nanoparticles against the influenza A virus	0
PP 8.12 – 00179 In Vitro Assay for Escape Pathways from Broadly Neutralizing Antibodies	0
Heat shock protein: a double-edged sword linking innate immunity and hepatitis B virus infection	0
World AIDS Conference 2022 – updates on antiretroviral therapy	0
Antiviral strategies targeting herpesviruses	0
OP 4.5 – 00101 Comparative single-cell transcriptome and TCR profiling of HIV infected cells in the blood and cerebrospinal fluid of PLWH before and after ART	0
Identification of a pharmacological approach to reduce ACE2 expression and development of an in vitro COVID-19 viral entry model	0
Indomethacin inhibits human seasonal coronaviruses at late stages of viral replication in lung cells: Impact on virus-induced COX-2 expression	0
PP 1.31 – 00161 Chimeric proviral/human transcription events at the BACH2 integration locus in cellular models for chronic HIV infection	0
PP 6.6 – 00208 Construct a series of universal gRNAs targeting various regions within HIV	0
Mass immunisation to eradicate Japanese encephalitis: Real-world evidence from Guizhou Province in 2005–2021	0
Real-life study on the effectiveness and safety of sofosbuvir/velpatasvir-based antiviral agents for hepatitis C eradication in Chinese patients	0
PP 1.1 – 00009 TB-associated microenvironment promotes HIV latency in CD4+ T cells	0
PP4.1 – 00179 Distinct Immunity Signatures Uncover Diverse Profiles Among Elite HIV Controllers	0
Fixation and reversion of mutations in the receptor-binding domain of the SARS-CoV-2 spike protein: A 2020–2024 analysis	0
PP 3.18 – 00027 Role of Tunneling Nanotubes-like Structures during the Early Events of HIV Infection and viral reactivation	0
8.6 – 00097 Increased HIV-1 proviral reactivation and reservoir size in people with HIV on anticancer treatment	0
PP 1.30 – 00159 Dating HIV-1 reservoir formation in ARV-suppressed Ugandans	0
7.3 – 00050 Profound reduction of HIV-1 reservoir cells over three decades of antiretroviral therapy started in early infancy	0
HIV cure research in the time of COVID-19 - Antiretroviral therapy treatment interruption trials: A discussion paper	0
PP 4.21 – 00050 Seeding of long-lived HIV cellular reservoirs through differentiation of infected CCR5+CD4+ T cells into central memory cells	0